TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men age 18-60 years old~2. BMI ≥ 30 kg/m2~3. Waist circumference ≥ 102 cm~4. Peak GH value of ≤ 4.2 μg/l on standard GHRH-arginine stimulation test~Exclusion Criteria:~1. Obesity due to a known secondary cause (Cushing's syndrome, hypothyroidism, etc) or a history of gastric bypass procedure.~2. Subjects who have a known history of diabetes, fasting blood sugar \>125 mg/dl or using any anti-diabetic drugs.~3. Use of Aspirin, Clopidogrel (Plavix), Warfarin (Coumadin) or other anti-coagulants~4. Subjects on testosterone, glucocorticoids, anabolic steroids, GHRH, GH or IGF-1 within 3 months of enrollment.~5. Changes in lipid lowering or anti-hypertensive regimen within 3 months of screening~6. History of pituitary tumor, hypopituitarism, pituitary surgery, pituitary/brain radiation or traumatic brain injury or any other condition known to affect the GH axis.~7. Severe chronic illness including HIV, active malignancy or history of colon cancer.~8. Hemoglobin \< 9.0 g/dL, SGOT \> 2.5 x upper limit normal, Creatinine \>1.5 mg/dL, or PSA \>5 ng/ml.~9. Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.~10. Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient.~11. Contraindications to MRI scanning.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Growth Hormone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males or females~2. Age 18-50 years (incl)~3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl)~4. Subjects must be able to understand and comply with study requirements~Exclusion criteria:~Any deviation from healthy condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- High dose, fasted (Type: EXPERIMENTAL): 1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
- High dose, fed (Type: EXPERIMENTAL): 1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
- Low dose, fasted (Type: EXPERIMENTAL): 2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis B~* Biopsy performed within one year prior to screening or during screening~* ALT \> 1.5 x ULN~* HBeAg negative, anti-HBeAg positive~* HBV DNA \> 10E5 copies/ml~* Age 18-70 years~* Written informed consent~* Hepatic imaging without evidence of HCC~* All fertile males and females must be using two forms of effective contraception~Exclusion Criteria:~* Antiviral therapy against HBV within the previous 6 months; treatment with any investigational drug within 30 days of entry to this protocol~* Severe hepatitis activity as documented by ALT \> 10 x ULN~* Advanced liver disease~* Pre-existent leucopenia or thrombopenia~* Co-infection with HCV,HDV or HIV~* Other acquired or inherited causes of liver disease~* Alpha fetoprotein \> 50 ng/ml.~* Evidence of severe renal disease~* Hyper- or hypothyroidism~* Significant cardiovascular or pulmonary dysfunction, malignancy,immunodeficiency syndromes~* Immune suppressive treatment within the previous 6 months~* Contra-indications for alpha-interferon therapy~* Pregnancy, breast-feeding~* Any medical condition requiring chronic systemic administration of steroids~* Substance alcohol or drug abuse~* Subjects with clinically significant retinal abnormalities~* Subjects with clinically significant hearing abnormalities~* Hemoglobinopathies~* Subjects with known hypersensitivity to ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Ribavirin + Peg IFN
- 2 (Type: ACTIVE_COMPARATOR): Peg IFN + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis~* Inadequate response to anticholinergic medication used to treat overactive bladder~Exclusion Criteria:~* History or evidence of pelvic or urologic abnormality~* Previous or current diagnosis of bladder or prostate cancer~* Urinary tract infection at time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): botulinum toxin Type A (200U)
- 2 (Type: EXPERIMENTAL): botulinum toxin Type A (300U)
- 3 (Type: OTHER): placebo; botulinum toxin Type A (200U)
- 4 (Type: OTHER): placebo; botulinum toxin Type A (300U)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment~* At least one high-risk cytogenetic feature defined by the presence of 17p deletion, 11q deletion and/or p53 mutation~* Eastern Cooperative Oncology Group (ECOG) score of 0 to 2~Exclusion Criteria:~* Any major surgery, chemotherapy or immunotherapy within the last 21 days~* Evidence of hepatitis B virus, hepatitis C virus or known human immunodeficiency virus (HIV) infection~* Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded~* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)~* Previous therapy with ibrutinib, or any drug that specifically inhibits Bruton's tyrosine kinase (BTK)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ublituximab + Ibrutinib (Type: EXPERIMENTAL): Participants will receive ublituximab intravenous (IV) infusion, up to 150 milligrams (mg) once on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1 (Cycle duration=28 days) followed by 900 mg on Day 1 of Cycles 2 to 6 and 900 mg on Day 1 of every 3rd cycle thereafter for up to 62 months along with ibrutinib 420 mg capsules, orally, once daily (QD) in each 28-day cycle for up to 62 months.
- Ibrutinib (Type: ACTIVE_COMPARATOR): Participants will receive ibrutinib 420 mg capsules, orally, QD in each 28-day cycle up to 62 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of chronic schizophrenic disorder, according to the Diagnostic and Statistical Manual of Mental Diseases, 3rd edition (DSM-III-R) criteria and are inpatients at the beginning of study~* total score on the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) rating scale at study entry of \>=60 and \<=120~* females of childbearing age must demonstrate adequate birth control measures and have a negative pregnancy test before study entry.~Exclusion Criteria:~* Patients with mental disorders other than chronic schizophrenic disorder~* patients with clinically significant organic or neurological diseases~* patients with epilepsy~* history of alcohol or drug abuse history within the 6 months before study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant meets the Diagnostic and Statistical Manual of Mental Disorders (Edition 4) criteria for schizophrenia~* Participant is previously non-acute (on the same antipsychotic medication used for the treatment of schizophrenia and Clinical Global Impression-Severity \[CGI-S\] change less than or equal to 1 in the past 4 weeks before enrollment) and has been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time prior to enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of effectiveness, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication~* Participant is healthy on the basis of a physical examination and vital signs at screening~* Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study~* Participants must be willing and able to fill out self-administered questionnaires~Exclusion Criteria:~* Participants on clozapine, any conventional depot neuroleptic or risperidone long-acting injection during the last 3 months~* Participants with serious unstable medical condition, including known clinically relevant laboratory abnormalities~* Participants with history or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body) and neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)~* Participants judged to be at high risk for adverse events, violence or self-harm~* Participants with a current use or known history (over the past 6 months) of substance dependence according to Diagnostic and Statistical Manual of Mental Disorders (Edition 4) Criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paliperidone Extended Release (ER) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Definitive diagnosis of Crohn's disease confirmed (at least 3 months prior to study entry) either by radiological, endoscopic or histological evidence, affecting the terminal ileum (L1), colon (L2) or ileocolon (L3\*. \*Vienna Classification (1998)~* Active Crohn's disease (≥ 220 and ≤ 450) scored over the 7 days prior to the first dose of study drug.~* Male and female aged 18 years or above at screening.~* Patients who meet all concomitant medication criteria in the protocol specified table. For all drugs being taken at screening, the patient should be able to remain on a stable dose throughout the duration of the study, although steroids may be tapered starting at Weeks 8 to 12.~Exclusion Criteria:~* Crohn's Disease Related~* Fistula abscess present at screening.~* Stricturing type disease with symptoms or signs of non-inflammatory mechanical obstruction or bowel perforation in last 3 months.~* Short bowel syndrome.~* Functional colostomy or ileostomy (note: patients who have had a temporary stoma in the past, which has been reversed, are eligible to enter the study).~* Positive stool laboratory results for enteric pathogens.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD~Exclusion Criteria:~* History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium 200 μg once-daily (Type: EXPERIMENTAL): Aclidinium bromide 200 μg once-daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once-daily via inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients in ASA score I - III, planned to be treated with open radical nephrectomy or nephron-sparing surgery having renal cell carcinoma~Exclusion Criteria:~* patients in ASA score IV-V,~* patients with advanced tumour thrombus in vena cava inferior,~* patients with high risk for bleeding~* patients with previous chronic pain symptoms~* patients having drug abuse~* patients having cognitive deficiencies or dementia disease~* patients with any contraindication of either spinal or epidural anesthesia~* patients younger than 18 years and pregnant woman~* patients having a weight less than 45 kg or weight over 120 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spinal anesthesia (Type: EXPERIMENTAL): The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( \< 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
- Epidural anesthesia (Type: ACTIVE_COMPARATOR): Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a current diagnosis of major depressive disorder~* Has a primary care physician at Northwestern University in Illinois, or one of a number of approved community clinics in Chicago.~* Resides in Illinois~* Has a telephone~* Speaks and reads English~Exclusion Criteria:~* Hearing, voice, or visual impairment~* Meets criteria for dementia~* Diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current substance abuse, or other condition for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous~* Currently receiving individual psychotherapy or planning to receive psychotherapy during the treatment phase of the study~* Planning to be out of town or unavailable for treatment for 4 weeks or more during the scheduled treatment time~* Recent history of suicide attempts or is severely suicidal~* Initiated treatment with an antidepressant in the 2 months before study entry (antidepressant medication is not exclusionary)~* Depression determined to be primarily of an organic etiology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Telephone-administered CBT (Type: EXPERIMENTAL): Participants will receive telephone-administered cognitive behavioral therapy.
- Face-to-face CBT (Type: ACTIVE_COMPARATOR): Participants will receive face-to-face cognitive behavioral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male and female subjects aged 18 to 55 years with established diagnosis of MS McDonald 2010 with relapsing course from onset (i.e., RRMS and SPMS with superimposed relapses).~Subjects must have active disease evidenced by one or more MS attacks with onset within the period of 12 to 1 months prior to randomization, or by two or more MS attacks with onset within the 24 to 1 months prior to randomization, or with one or more gadolinium-enhancing (Gd+) lesion(s) of the brain on an MRI performed within 6 months prior to randomization.~Enrolled subjects must be ambulatory (EDSS score of up to 5.5 inclusive) and may be treatment-naïve or previously treated with MS disease modifying therapy.~Exclusion Criteria:~Subjects with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic,ophthalmological conditions) or lactating or pregnant women are not eligible to enter the study.~Subjects with contraindications to MRI or with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study are not eligible to enter the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ponesimod (Type: EXPERIMENTAL): Subjects to receive 20 mg ponesimod
- Teriflunomide (Type: ACTIVE_COMPARATOR): Subjects to receive 14 mg teriflunomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female of at least 18 years of age~* Confirmed diagnosis of portopulmonary hypertension~Main Exclusion Criteria:~* Severe hepatic impairment~* Severe obstructive or restrictive lung disease~* Pulmonary veno-occlusive disease~* Systolic blood pressure (SBP) \< 90 mmHg at Screening~* ALT/AST \>= 3 x ULN~* Bilirubin \>= 3 mg/dL at Screening~* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational treatment (Type: EXPERIMENTAL): Macitentan film-coated tablet 10 mg once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete